What Has Been The Evolution of the Alzheimers Disease Diagnostic Market in Recent Years?
The alzheimers disease diagnostic market has seen considerable growth due to a variety of factors.
• In recent years, the market size of Alzheimer's disease diagnostics has seen accelerated growth. The market, which was valued at $6.56 billion in 2024, is set to climb to $7.28 billion in 2025, marking a compound annual growth rate (CAGR) of 11%.
This progression during the historical phase can be linked to the escalating prevalence of Alzheimer's disease and dementia, heightened cognizance about the significance of early detection for effective management, breakthroughs in imaging technologies like MRI and PET scans, amplified investment in research and development pertaining to neurodegenerative diseases, along with upsurges in government initiatives and funds directed towards Alzheimer's research and diagnostics.
What Are the Future Growth Projections for the Alzheimers Disease Diagnostic Market Size?
The alzheimers disease diagnostic market is expected to maintain its strong growth trajectory in upcoming years.
• The future for the diagnostic market for Alzheimer's disease is looking quite promising. The market size is predicted to bloom swiftly in the coming years, eventually reaching $10.91 billion in 2029 with 10.7% CAGR. Factors such as the invention of blood-based biomarkers for non-intrusive diagnosis, the escalating demand for personal medication and precision diagnostics, AI and machine learning's alliance with diagnostic tools for preliminary detection, digital health technologies' blossoming appeal in remote monitoring and diagnosis, and the enlarging healthcare infrastructure in nascent markets to heighten accessibility are significant determinants of this forecasted growth. There are noteworthy trends expected during this period such as emerging multi-modal diagnostic methods that amalgamate imaging, biomarkers and cognitive tests, amplified emphasis on point-of-care diagnostic solutions for instant results, invention of wearable gadgets for constant monitoring of cognitive health. An increase in cooperation between biotech companies and research institutions for pioneering solutions, and a surge in direct-to-consumer genetic testing for Alzheimer's risk evaluation are emerging trends.
What Are The Core Factors Supporting Growth In The Alzheimers Disease Diagnostic Market?
The rise in chronic illnesses is forecasted to fuel the expansion of the Alzheimer's disease diagnostic market. Chronic ailments, which are health conditions lasting more than three months, are increasing due to a combination of lifestyle choices, environmental factors, genetic susceptibility, and economic conditions. The occurrence of persistent illnesses, such as cardiovascular issues, diabetes, and high blood pressure, raises the risk of developing Alzheimer's disease and other types of dementia. As per a January 2022 report by the American Heart Association Inc., a nonprofit organization in the US, the number of brain disorders in the US is projected to escalate to 9.3 million by 2060 and the growth of this type of disease is continuous. Worldwide, one in six people already suffers from a brain disease. By 2021, the global count is anticipated to hit 1 billion. Thus, the escalating prevalence of chronic diseases is anticipated to stimulate the growth of the Alzheimer's disease diagnostic market.
What Are The Major Segments Within The Global Alzheimers Disease Diagnostic Market?
The alzheimer’s disease diagnostic market covered in this report is segmented –
1) By Type: Triage, Diagnosis, Screening
2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests
3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center
Subsegments:
1) By Triage: Cognitive Testing, Imaging Techniques
2) By Diagnosis: Biomarker Testing, Neuroimaging
3) By Screening: Neuropsychological Testing, Genetic Testing
Pre-Book The Alzheimers Disease Diagnostic Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Alzheimers Disease Diagnostic Market?
Leading businesses in the Alzheimer’s disease diagnostic market are prioritizing enhancements in blood-based biomarker tests. This advancement could streamline Alzheimer's disease diagnosis by diminishing the need for more invasive methods and ensuring patients receive timely treatment. For example, Quanterix, a biotech research company from the US, introduced the LucentAD p-Tau 217 test in October 2023. This test is a biomarker for Alzheimer's pathology featuring clinical blood sensitivity and specificity. The conventional techniques for investigating cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) or lumbar punctures, are expensive, invasive, and limited in availability. Moreover, the LucentAD p-Tau 217 test blends Quanterix's extremely sensitive SimoaÒ technology with J&J Innovative Medicine's thoroughly examined p-Tau 217 antibodies to achieve superior precision and a simpler process.
Who Are the Key Players In The Alzheimers Disease Diagnostic Market?
Major companies operating in the alzheimer’s disease diagnostic market are:
• Pfizer Inc.
• AbbVie
• Bristol Myers Squibb Company
• Hoffmann-La Roche
• Eli Lilly and Company
• Siemens Healthineers AG
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Daiichi Sankyo Co.
• Sysmex
• Lantheus
• Quanterix
• FujireBio
• TauRx Pharmaceuticals Ltd
• AC Immune
• C2N diagnostics
• AXON Neuroscience
• Neuro-Bio Ltd
• Anavex Life Sciences Corp.
• Treventis Corporation
What Is The Most Dominant Region In The Alzheimers Disease Diagnostic Market?
North America was the largest region in the alzheimer's disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
